StreetInsider.com News Articles

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Fri, 11 Sep 2026 07:01:00 -0400

WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the H.C. Wainwright 28th Annual Global Investment Conference, taking place in New York City September 14-16, 2026.

On Wednesday, September 16, 2026, at 10:30 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Charles Morris, MBChB, MRCP. Chief Medical Officer, Peggy Scherle, Ph.D., Chief Scientific Officer, and Bryant Lim, Chief Financial Officer will participate in a fireside chat.

A live webcast of the fireside

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Fri, 11 Sep 2026 07:01:00 -0400

A live webcast of the fireside

Form 8-K Prelude Therapeutics For: Sep 10

Thu, 10 Sep 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260910/27045140.html

FDA clears Prelude Therapeutics to begin trial of KAT6A degrader

Thu, 10 Sep 2026 07:02:40 -0400

Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced that the U.S. Food and Drug Administration cleared the company to proceed with a Phase 1 study of PRT13722, an oral KAT6A selective degrader being developed for patients with HR-positive, HER2-negative breast cancer.

The company said it expects to begin enrolling patients in the fourth quarter of 2026, according to a press release issued Sept. 10, 2026.

The Phase 1 study is described as a first-in-human, open-label, multicenter trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of PRT13722. The drug will be assessed both as a monotherapy and in combination with endocrine

FDA clears Prelude Therapeutics to begin trial of KAT6A degrader

Thu, 10 Sep 2026 07:02:40 -0400

The company said it expects to begin enrolling patients in the fourth quarter of 2026, according to a press release issued Sept. 10, 2026.

FDA clears Prelude Therapeutics to begin trial of KAT6A degrader

Thu, 10 Sep 2026 07:02:40 -0400

The company said it expects to begin enrolling patients in the fourth quarter of 2026, according to a press release issued Sept. 10, 2026.

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

Thu, 10 Sep 2026 07:01:00 -0400

Phase 1 study of PRT13722 in patients with HR+ breast cancer anticipated to begin enrolling patients in the fourth quarter of 2026.

WILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company to proceed with a Phase 1 study under its Investigational New Drug Application (IND) for PRT13722, an oral KAT6A selective degrader being developed for the treatment of patients with HR+/HER2- breast cancer. The Company expects to begin enrolling patients in the fourth quarter of 2026.

"Recent

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

Thu, 10 Sep 2026 07:01:00 -0400

Phase 1 study of PRT13722 in patients with HR+ breast cancer anticipated to begin enrolling patients in the fourth quarter of 2026.

"Recent

Form 10-Q Prelude Therapeutics For: Jun 30

Tue, 11 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26901915.html

Form 10-Q Prelude Therapeutics For: Jun 30

Tue, 11 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26901915.html

Form 8-K Prelude Therapeutics For: Aug 11

Tue, 11 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260811/26901753.html

Form 8-K Prelude Therapeutics For: Aug 11

Tue, 11 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260811/26901753.html

Prelude Therapeutics Incorporated (PRLD) Tops Q2 EPS by 9c

Tue, 11 Aug 2026 07:18:33 -0400

Prelude Therapeutics Incorporated (NASDAQ: PRLD) reported Q2 EPS of ($0.14), $0.09 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $5.71 million.

For earnings history and earnings-related data on Prelude Therapeutics Incorporated (PRLD) click here.

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 07:00:00 -0400

The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Enrollment continues in Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

Current cash runway expected into the second quarter of 2028 with $155 million in cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 07:00:00 -0400

The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Enrollment continues in Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

Current cash runway expected into the second quarter of 2028 with $155 million in cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026

H.C. Wainwright Reiterates Buy Rating on Prelude Therapeutics (PRLD)

Wed, 29 Jul 2026 06:53:58 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $8.00 price target on Prelude Therapeutics (NASDAQ: PRLD).

The analyst commented: "Yesterday, Incyte announced that it has discontinued further development of INCB160058 (a JAK2V617F inhibitor) following a comprehensive review of available data and shall prioritize its next-generation JAK2V617F-targeted pipeline, with preclinical data expected for its next-generation JAK2V617F-targeted inhibitor in 2H26. We believe this announcement has positive read-through for Prelude given Incyte's exclusive option agreement, inked in November 2025, to acquire PRT12396, Prelude's JAK2V617F-selective JH2 inhibitor currently in Phase 1 development for polycythemia vera (PV) and myelofibrosis (MF). Should Incyte exercise its

H.C. Wainwright Reiterates Buy Rating on Prelude Therapeutics (PRLD)

Wed, 15 Jul 2026 07:39:13 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $8.00 price target on Prelude Therapeutics (NASDAQ: PRLD).

The analyst commented: ' Earlier this month, CSPC Pharmaceutical (HKG: 1093; not rated) announced that it has initiated a Phase 1 trial in China (NCT07692776) evaluating SYH-2095 (a KAT6A/B inhibitor) for the treatment of advanced malignant tumors as a monotherapy or in combination regimens. With SYH-2095 entering clinical testing, the number of KAT6 inhibitors currently in development has increased to 12. Although competition within the KAT6 inhibitor landscape is growing, we highlight the encouraging preclinical data that Prelude presented at AACR 2026 for

Form SCHEDULE 13G Prelude Therapeutics Filed by: Soleus Private Equity Fund III, L.P.

Wed, 08 Jul 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260708/26748383.html

Form SCHEDULE 13G Prelude Therapeutics Filed by: Soleus Private Equity Fund III, L.P.

Wed, 08 Jul 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260708/26748383.html

Prelude Therapeutics (PRLD) Reiterated at Market Outperform by Citizens

Wed, 01 Jul 2026 04:53:20 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $6.00 price target on Prelude Therapeutics (NASDAQ: PRLD).

The analyst commented, "File IND for KAT6A degrader PRT13722 and initiate Phase 1 study. Prelude’s second clinical program since its strategic reset is PRT13722, a highly selective KAT6A degrader for ER+/HER2− breast cancer. AACR 2026 preclinical data showed picomolar KAT6A degradation with high selectivity over KAT6B and other MYST proteins, deeper and more complete tumor regressions than Pfizer’s KAT6A/B inhibitor prifetrastat in head-to-head ER+/HER2− CDX and PDX models, and 100% (8/8) durable complete responses in a posttamoxifen PDX model. As importantly, PRT13722 showed

Form 4 Prelude Therapeutics For: Jun 09 Filed by: 667, L.P.

Wed, 10 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260610/26630550.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: 667, L.P.

Wed, 10 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260610/26630550.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Babler Martin

Wed, 10 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260610/26630077.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Babler Martin

Wed, 10 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260610/26630077.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Dorton Katina

Wed, 10 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260610/26630103.html